Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | DHODH | Q02127 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CDC25A | P30304 | 1/20 | 0.38 |
| ▸ | CDC25B | P30305 | 1/20 | 0.38 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.38 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
| ▸ | VKORC1 | Q9BQB6 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3410244 | 0.85 | MAPT (0.47) | MEN1KMT2AMAPTCYP3A4ALDH1A1 | |
| SCHEMBL4623305 | 0.83 | TRPA1 (0.43) | — | |
| SCHEMBL6138617 | 0.82 | — | — | |
| SCHEMBL1702559 | 0.82 | — | — | |
| SCHEMBL526546 | 0.77 | — | — | |
| SCHEMBL7822554 | 0.74 | — | — | |
| SCHEMBL482794 | 0.73 | MAOB (0.30) | MAOB | |
| SCHEMBL482877 | 0.73 | MAOB (0.30) | MAOB | |
| SCHEMBL9199675 | 0.73 | MAOB (0.30) | MAOB | |
| SCHEMBL20778 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024403-A1 | Compositions and Methods for Managing Weight | UNIGEN, INC. (US) | 2024-01-25 | — | — | US | claimed |
| CN-113476499-A | Compositions and methods for weight management | 尤妮金公司 | 2021-10-08 | — | — | CN | claimed |
| CN-107281490-B | Compositions and methods for weight management | 尤妮金公司 | 2021-08-20 | — | — | CN | claimed |
| US-20180099019-A1 | Compositions and Methods for Managing Weight | UNIGEN, INC. (US) | 2018-04-12 | — | — | US | claimed |
| US-20140004215-A1 | COMPOSITIONS AND METHODS FOR MANAGING WEIGHT | UNIGEN, INC. (KR) | 2014-01-02 | — | — | US | claimed |
| WO-2013181296-A2 | COMPOSITIONS AND METHODS FOR MANAGING WEIGHT | UNIGEN, INC. (US) | 2013-12-05 | — | — | WO | claimed |
| US-12042523-B2 | Compositions and methods for managing or improving bone disorders, joint disorders, cartilage disorders, or a combination thereof | UNIGEN, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240024403-A1 | Compositions and Methods for Managing Weight | UNIGEN, INC. (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240024403-A1 | Compositions and Methods for Managing Weight | UNIGEN, INC. (US) | 2024-01-25 | — | — | US | disclosed |
| CN-117224593-A | Compositions and methods for managing or improving bone disorders, cartilage disorders, or both | 尤尼根公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-116785342-A | Compositions and methods for managing or improving bone disorders, cartilage disorders, or both | 尤尼根公司 | 2023-09-22 | — | — | CN | disclosed |
| US-20230201295-A1 | Compositions and Methods for Managing or Improving Bone Disorders, Joint Disorders, Cartilage Disorders, or a Combination Thereof | UNIGEN, INC. (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230190852-A1 | COMPOSITIONS AND METHODS FOR JOINT HEALTH | UNIGEN, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2013181296-A2 | COMPOSITIONS AND METHODS FOR MANAGING WEIGHT | UNIGEN, INC. (US) | 2013-12-05 | — | — | WO | disclosed |
| EP-0151702-B1 | ALPHA-HYDROXYKETONE ACETALS | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1987-11-25 | — | — | EP | disclosed |
| EP-0048136-B1 | PROCESS FOR PREPARING ALPHA-AROMATIC GROUP SUBSTITUTED ALKANOIC ACIDS OR ESTERS THEREOF | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1986-06-11 | — | — | EP | disclosed |
| US-4539420-A | Optically active 1-aromatic-group-substituted-1-alkanones and methods for their manufacture | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1985-09-03 | — | — | US | disclosed |
| EP-0151702-A2 | Alpha-hydroxyketone acetals | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1985-08-21 | — | — | EP | disclosed |
| EP-0067698-A2 | Optically active 1-aromatic-group-substituted-1-alkanones and methods for their manufacture | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1982-12-22 | — | — | EP | disclosed |
| EP-0048136-A2 | Process for preparing alpha-aromatic group substituted alkanoic acids or esters thereof | SYNTEX PHARMACEUTICALS INTERNATIONAL LIMITED (BM) | 1982-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12042523-B2 | Compositions and methods for managing or improving bone disorders, joint disorders, cartilage disorders, or a combination thereof | MATR3, ACACA, COL2A1 | MEN1 2574/4885KMT2A 2507/4885DHODH 3651/4885 |
| US-20240024403-A1 | Compositions and Methods for Managing Weight | LIPE, PNLIP, LIPC | MEN1 3871/4885KMT2A 2720/4885DHODH 2123/4885 |
| US-20180099019-A1 | Compositions and Methods for Managing Weight | LIPE, PNLIP, LIPC | MEN1 3871/4885KMT2A 2720/4885DHODH 2123/4885 |
| US-20140004215-A1 | COMPOSITIONS AND METHODS FOR MANAGING WEIGHT | LIPE, PNLIP, LIPC | MEN1 3871/4885KMT2A 2720/4885DHODH 2123/4885 |
| US-20230201295-A1 | Compositions and Methods for Managing or Improving Bone Disorders, Joint Disorders, Cartilage Disorders, or a Combination Thereof | MATR3, ACACA, COL2A1 | MEN1 2574/4885KMT2A 2507/4885DHODH 3651/4885 |
| US-20230190852-A1 | COMPOSITIONS AND METHODS FOR JOINT HEALTH | PTGES, PTGES3, PTGES2 | MEN1 3730/4885KMT2A 3613/4885DHODH 2079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.